Denali Therapeutics Inc (NASDAQ:DNLI) saw a significant growth in short interest in December. As of December 29th, there was short interest totalling 2,291,611 shares, a growth of 1,101.8% from the December 15th total of 190,677 shares. Currently, 4.5% of the company’s shares are sold short. Based on an average daily trading volume, of 434,780 shares, the days-to-cover ratio is currently 5.3 days.
Shares of Denali Therapeutics (DNLI) opened at $16.53 on Friday. The stock has a market cap of $1,450.00 and a P/E ratio of -16.05. Denali Therapeutics has a 52-week low of $14.72 and a 52-week high of $22.95.
In other news, major shareholder Douglas K. Bratton acquired 275,000 shares of Denali Therapeutics stock in a transaction on Tuesday, December 12th. The stock was bought at an average cost of $18.00 per share, with a total value of $4,950,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Denali Therapeutics Company Profile
Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.